secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viatris Inc (VTRS)
CIK:        0001792044
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001792044-24-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viatris Q3 2024: Revenue $3.8B, GAAP EPS $0.08, Adjusted EPS $0.75, Repaid $1.9B Debt
--------------------------------------------------------------------------------

- Total revenues $3.8B, operational revenue growth ~3% on divestiture-adjusted basis; new product revenues $133M.
- GAAP net earnings $95M ($0.08 diluted EPS); adjusted EBITDA ~$1.3B (+4% divestiture-adjusted); adjusted EPS $0.75 (+6%).
- Repaid ~$1.9B debt including make-whole call; expects to reach ~3.0x gross leverage target by year-end.
- Entered exclusive licensing agreement with Lexicon for sotagliflozin outside U.S. and Europe.
- Reaffirms 2024 full-year outlook: ~2% revenue growth on divestiture-adjusted operational basis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792044/000179204424000031/0001792044-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792044/000179204424000031/vtrs-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001792044-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer